Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Julianne Chen"'
Autor:
Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, Uday R. Popat, Courtney D. DiNardo, Naval Daver, Musa Yilmaz, Hussein A. Abbas, Nicholas Short, Ghayas C. Issa, Elias Jabbour, Sherry A. Pierce, Julianne Chen, Ricky Garcia, Marina Konopleva, Guillermo Garcia-Manero, Amin M. Alousi, Elizabeth J. Shpall, Richard E. Champlin, Gautam Borthakur, Farhad Ravandi, Tapan M. Kadia
Publikováno v:
Blood. 140:4872-4875
Autor:
Alejandro Marinos, Jeremy L Ramdial, Rima M. Saliba, Fareed Khawaja, Amin M. Alousi, Gabriela Rondon, Julianne Chen, Celina Ledesma, Dr. Roy F. Chemaly, Richard E. Champlin, David Marin, May Daher, Katayoun Rezvani, Elizabeth J. Shpall
Publikováno v:
Transplantation and Cellular Therapy. 29:S339-S340
Autor:
Uday R. Popat, Rima M. Saliba, Rohtesh S. Mehta, Amin M. Alousi, Gheath Al-Atrash, Qaiser Bashir, Julianne Chen, Alison M. Gulbis, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa F. Khouri, Jitesh D. Kawedia, David Marin, Yago Nieto, Amanda Olson, Betul Oran, Jeremy Ramdial, Neeraj Y. Saini, Samer A. Srour, Katayoun Rezvani, Muzaffar H. Qazilbash, Hagop Kantarjian, Borje S. Andersson, Richard E. Champlin, Elizabeth J. Shpall
Publikováno v:
Transplantation and Cellular Therapy. 29:S164-S165
Autor:
Julianne Chen, Qaiser Bashir, Samer A. Srour, Richard E. Champlin, Rohtesh S. Mehta, Betul Oran, Gabriela Rondon, Uday R. Popat, Ankur Varma, Stefan O. Ciurea, Amin M. Alousi, Piyanuch Kongtim, Naval Daver, Chitra Hosing, Amanda Olson, Marina Konopleva
Publikováno v:
Blood
The optimal conditioning regimen for older patients with acute myeloid leukemia (AML) remains unclear. In this study, we compared outcomes of AML patients >60 years of age undergoing allogenic hematopoietic stem cell transplantation at our institutio
Autor:
Gheath Alatrash, Chantal Saberian, Roland Bassett, Peter F. Thall, Celina Ledesma, Yoshimi Lu, May Daher, Benigno C. Valdez, Jitesh Kawedia, Uday Popat, Rohtesh Mehta, Betul Oran, Yago Nieto, Amanda Olson, Paolo Anderlini, David Marin, Chitra Hosing, Amin M. Alousi, Elizabeth J. Shpall, Gabriela Rondon, Julianne Chen, Muzaffar Qazilbash, Richard E. Champlin, Partow Kebriaei
Publikováno v:
Transplantation and Cellular Therapy. 28:501.e1-501.e7
Conditioning regimens play a major role in determining disease outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The use of i.v. busulfan (Bu) as part of conditioning chemotherapy has been shown to be effective in con
Autor:
Supawee Saengboon, Nicholas Cox, Amanda Olson, Fareed Khawaja, May Daher, Jin Seon Im, Julianne Chen, Chitra Hosing, Muzaffar H. Qazilbash, Elizabeth J Shpall, Richard E Champlin, Samer A Srour
Publikováno v:
Transplantation and Cellular Therapy. 28:S367
Autor:
Julianne Chen, Gabriela Rondon, Partow Kebriaei, Stefan O. Ciurea, Betul Oran, Kai Cao, Mohammed El Shazly, Michele Alvarez, Chitra Hosing, Denái R. Milton, Majdi Aljadayeh, Richard E. Champlin, Issa F. Khouri, Jorge M. Ramos Perez, Uday R. Popat, Marina Konopleva, Jin Im, Piyanuch Kongtim, Maria C.B. Bittencourt, Qaiser Bashir, Gheath Alatrash, Rohtesh S. Mehta
Publikováno v:
Blood advances, vol 2, iss 17
Introduction An HLA-matched unrelated donor (MUD) has been accepted as the next best option for patients who do not have a matched-related donor (MRD) available. However, identification of a MUD may be challenging due to donor availability for some p
Autor:
Stefan O. Ciurea, Piyanuch Kongtim, Kai Cao, Doris Soebbing, Jolie Schafer, Dean A. Lee, Samer A. Srour, Richard E. Champlin, Julianne Chen, Marina Konopleva, Elizabeth J. Shpall
Publikováno v:
Transplantation and Cellular Therapy. 27:S77-S78
Autor:
Partow Kebriaei, Issa F. Khouri, Julianne Chen, Jorge M. Ramos Perez, Uday R. Popat, Keyur P. Patel, Gabriela Rondon, Brion Randolph, Chitra Hosing, Jin Im, Stefan O. Ciurea, Gheath Alatrash, Haitham Khogeer, Rohtesh S. Mehta, Richard E. Champlin, Abhishek Chilkulwar, Rima M. Saliba, Qaiser Bashir, Abdul Rashid Shah
Publikováno v:
Blood. 131:2989-2992
TO THE EDITOR: Allogeneic hematopoietic stem-cell transplantation (ASCT) is curative treatment for patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), who otherwise have dismal outcomes.[1][1][⇓][2][⇓][3]-[4][4
Autor:
Amin M. Alousi, Julianne Chen, Celina Ledesma, Roy F. Chemaly, Jeremy Ramdial, Elizabeth J. Shpall, Rima M. Saliba, Gabriela Rondon, Richard E. Champlin
Publikováno v:
Blood
We are in the midst of a pandemic with the COVID-19 virus, a pathogen with potential severe manifestations. A major clinical question is whether it is safe to undergo hematopoietic stem cell transplantation (HSCT) shortly after COVID-19 infection. A